Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

7.88USD
15 Dec 2017
Change (% chg)

$-0.13 (-1.62%)
Prev Close
$8.01
Open
$8.10
Day's High
$8.10
Day's Low
$7.50
Volume
8,783
Avg. Vol
21,012
52-wk High
$21.59
52-wk Low
$7.22

Latest Key Developments (Source: Significant Developments)

Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr
Monday, 13 Nov 2017 09:05am EST 

Nov 13 (Reuters) - Gemphire Therapeutics Inc :Gemphire Therapeutics Inc qtrly loss per share $0.82‍​.  Full Article

Gemphire announces plans to advance gemcabene into phase 3 clinical development
Tuesday, 19 Sep 2017 04:01pm EDT 

Sept 19 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces plans to advance gemcabene into phase 3 clinical development.Gemphire Therapeutics Inc - ‍End of phase 2 meetings planned for early 2018​.Says gemcabene successfully achieved primary endpoint in two recently completed phase 2B studies.Gemphire Therapeutics - Results from all 20 clinical studies in 956 patients were exposed to gemcabene have demonstrated gemcabene is well tolerated and safe​.Gemphire-New analysis shows 600 mg of gemcabene reduced ldl-c by 21% in hypercholesterolemic patients, by 25% in mixed dyslipidemic patients in trials.Gemphire - Also plans to develop gemcabene as monotherapy or as add-on therapy to diet and other lipid lowering therapies for treatment of SHTG.  Full Article

Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​
Friday, 1 Sep 2017 04:53pm EDT 

Sept 1 (Reuters) - Gemphire Therapeutics Inc :Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​.  Full Article

Gemphire Therapeutics Inc posts Q2 net loss $0.99/shr
Monday, 14 Aug 2017 06:00am EDT 

Aug 14 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces second quarter 2017 financial results and provides corporate update.Gemphire Therapeutics Inc - qtrly net loss per share$ 0.99.Gemphire Therapeutics -‍ believes existing cash is sufficient to fund operations through completion of planned nash clinical trial anticipated in H2 2018.Gemphire Therapeutics - also ‍believes existing cash is sufficient to fund operations through completion of remaining dyslipidemia trial​.  Full Article

Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients
Monday, 7 Aug 2017 06:00am EDT 

Aug 7 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients.Gemcabene met primary endpoint and demonstrated a statistically significant lowering in LDL-C.There were no serious adverse events in study.Three subjects discontinued from study, 1 from Gemcabene and 2 from placebo groups.Gemphire Therapeutics - will perform additional analyses to thoroughly evaluate results of trial, once additional analyses complete, will provide update.  Full Article

Gemphire enters into $15 mln term loan agreement with Silicon Valley Bank
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Gemphire Therapeutics Inc :Gemphire enters into $15 million term loan agreement with silicon valley bank.Gemphire therapeutics inc - ‍immediately drew $10 million upon execution of loan agreement on july 24, 2017​.Gemphire therapeutics inc - ‍term loan will mature on february 1, 2021​.  Full Article

Gemphire announces top-line data from COBALT-1 phase 2b clinical trial in HoFH patients
Wednesday, 28 Jun 2017 04:01pm EDT 

June 28 (Reuters) - Gemphire Therapeutics Inc ::Gemphire announces top-line data from cobalt-1 phase 2b clinical trial in hofh patients.Gemphire therapeutics inc - top-line data on ldl-c primary endpoint from completed open label phase 2b cobalt-1 trial.Gemphire therapeutics - adverse events (aes) were mild to moderate in intensity across all doses of gemcabene and consistent with previously reported aes.Gemphire therapeutics inc - there were no serious aes or withdrawals due to aes in cobalt-1 study.Gemphire therapeutics - data announced continue to demonstrate additive lipid lowering efficacy of gemcabene has been demonstrated in extensive clinical program to date.Gemphire therapeutics inc - hofh patients continue to have elevated ldl-c and additional therapies are needed to help these patients.  Full Article

Gemphire Therapeutics reports departure of CEO
Tuesday, 30 May 2017 04:01pm EDT 

May 30 (Reuters) - Gemphire Therapeutics ::Gemphire Therapeutics announces departure of its chief executive officer Mina Sooch.Gemphire Therapeutics Inc- ‍steven Gullans named interim president and chief executive officer until a search for his replacement is completed​.Gullans is managing director at excel Venture Management, Llc, which owns more than 5 pct of Gemphire's outstanding stock.  Full Article

Gemphire reports Q1 loss per share of $0.79
Tuesday, 9 May 2017 06:00am EDT 

May 9 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.79.Q1 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.Expects full year operating expenses and cash used in operating activities to be approximately double 2016 levels.Expect Q2 2017 operating expenses and cash used in operations to continue to be substantially above comparable prior period levels.Top-line results from cobalt-1 phase 2B trial are expected in late June 2017.Top-line results from royal-1 phase 2B trial are expected in Q3 of 2017.Have plans to launch a phase 2 clinical development program in nash this year.Top-line results from Indigo-1 phase 2B trial are targeted for Q1 of 2018 based on current pace of enrollment.Plan to initiate phase 2 clinical development program (Azure-1) in nash in second half of 2017.Cash and cash equivalents at March 31, 2017 totaled $29.3 million compared to $24.0 million at December 31, 2016.Existing cash, net proceeds from private placement sufficient to fund operations through completion of ongoing dyslipidemia trials.  Full Article

Gemphire Therapeutics files for resale of up to 2.3 mln shares
Thursday, 13 Apr 2017 05:25pm EDT 

Gemphire Therapeutics Inc :Gemphire Therapeutics files for resale of up to 2.3 million shares of co's common stock by selling stockholders - sec filing.  Full Article

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage: